Disease relevance of SLC16A3

• Of 6000 genes, 32 were hypoxia inducible in vitro more than two-fold, five of which were novel, including lactate transporter SLC16A3 and RNAse 4 [1].
• MCT1 and MCT4 were expressed in BM vesicles, but there was no difference in expression between the IUGR and AGA groups [2].

High impact information on SLC16A3

• CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression [3].
• We conclude that CD147 facilitates proper expression of MCT1 and MCT4 at the cell surface, where they remain tightly bound to each other [3].
• Testosterone increases lactate transport, monocarboxylate transporter (MCT) 1 and MCT4 in rat skeletal muscle [4].
• In contrast, there was a strong positive relationship between the testosterone-induced increments in MCT4 protein and the fast-twitch fibre composition of rat muscles [4].
• We have examined the effects of administration of testosterone for 7 days on monocarboxylate transporter (MCT) 1 and MCT4 mRNAs and proteins in seven metabolically heterogeneous rat hindlimb muscles and in the heart [4].

Biological context of SLC16A3

• Expression of MCT3 mRNA increased over time as ARPE-19 cells established a differentiated phenotype [5].
• Inhibition of L-lactic acid transport mediated by MCT4 might to lead to collapse of muscle homeostasis [6].
• Exercise training can increase the expression of both MCT1 and MCT4 in human muscle, although the extent of this up-regulation may be related to the intensity of training [7].
• These genes are of special interest, because their products have important roles in cellular glucose metabolism, from glucose uptake (GLUT1) to glycolysis (PFKP) and lactate export (MCT4) [8].

Anatomical context of SLC16A3

• Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle [9].
• MCT3 is uniquely expressed in the retinal pigment epithelium [10].
• Expression of monocarboxylate transporter 4 in human platelets, leukocytes, and tissues assessed by antibodies raised against terminal versus pre-terminal peptides [11].
• The results of a previous study showing a K(m) value of 28.5 mM in hMCT4-expressed oocytes [6].
• The aim of this study was to establish an MCT4 transfected cell line and to clarify the transport mechanism of L-lactic acid and the effects of statins on this transport system [6].

Other interactions of SLC16A3

• CONCLUSIONS: These studies demonstrate for the first time that human RPE expresses two proton-coupled monocarboxylate transporters: MCT1 in the apical membrane and MCT3 in the basolateral membrane [5].
• In contrast, MCT3 and MCT4 harbor dominant sorting information that cotargets CD147 to the basolateral membrane in both epithelia [12].
• MCT1 antibody labeled the apical membrane of the RPE intensely, whereas MCT3 labeling was restricted to the basolateral membrane [5].
• MCT2 was localized in the postsynaptic membrane of parallel fiber-Purkinje cell synapses and MCT4 was situated in the membrane of glial cells in the cerebellum [13].

Analytical, diagnostic and therapeutic context of SLC16A3

• Western blot analysis revealed that ARPE-19 cells expressed high levels of MCT1 and MCT4 but very little MCT3 protein [5].

References